Therefore, it is wise to investigate the lack/presence of sortilin in patients with MCL and MZL; which may add another tumor marker to the current diagnostic panel for differentiating CLL from other Non-Hodgkin’s lymphomas. This evidence concerns the gene SORT1 and B-cell chronic lymphocytic leukemia.